Ticker: AVDL

Avadel Pharmaceuticals

Pharma Healthcare Drug Manufacturers - Specialty & Generic

Price 21.64

Reco Sell Potential 58 Risk 70 Updated 2026-07-27

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Avadel Pharmaceuticals is a healthcare company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Its core products include the sodium oxybate formulation, which targets narcolepsy, and other specialty pharmaceuticals. The company primarily generates revenue through product sales and licensing agreements.

Investment Profile

The investment profile of Avadel Pharmaceuticals is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income, as it does not currently offer dividends.

Category: Pharma Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Investment style: Growth Horizon: Medium-term Company type: Niche Player Experience: Basic

Fundamental metrics (experimental) Updated: 2026-07-22

EPS (TTM) — earnings per share for the last 12 months, $: 0.00
Revenue QoQ — quarter-over-quarter revenue growth: 13.7%
EPS surprise: -162.5%
20d volatility: 0.0%

AI recommendation changes

Date	Before	After	Reason
2026-07-23	Hold	Sell	Weak fundamentals and high risk limit upside potential.
2026-07-14	Sell	Hold	Weak fundamentals with uncertain market conditions.
2026-07-07	Hold	Sell	Weak fundamentals and high risk limit upside potential.
2026-06-23	Sell	Hold	Weak fundamentals and high risk limit upside potential.
2026-06-15	Hold	Sell	Weak fundamentals and high risk limit upside potential.
2026-05-08	—	Hold	Weak fundamentals and high risk offset potential upside.
2026-05-08	Hold	Hold	Компания показывает положительную динамику роста за последние 60 и 120 дней, однако низкий EPS и отрицательный сюрприз по доходам указывают на определенные риски.
2026-03-27	Buy	Hold	Компания показывает рост за последние 60 и 120 дней, однако низкий EPS и высокая степень неожиданности в отчетах указывают на потенциальные риски.
2026-02-12	Hold	Buy	Компания демонстрирует значительный рост за последние 120 дней и положительную динамику выручки, что указывает на потенциал для дальнейшего роста. Низкий риск также делает её привлекательной для инвестиций.
2026-02-02	Buy	Hold	Компания демонстрирует значительный рост за последние 120 дней, что может указывать на положительные перспективы. Однако отсутствие данных по EPS и выручке создает определенные риски.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2025-11-20	Wells Fargo	Target Raised	20 → 22.5	23.015
2025-10-28	UBS	Update	— → 20	18.56
2025-10-23	H.C. Wainwright	Rating Downgraded	— → 20	18.525
2025-10-23	Leerink Partners	Rating Downgraded	— → 18.5	18.525
2025-10-22	Jefferies	Rating Downgraded	— → 20	18.5492
2025-09-02	Wells Fargo	Update	— → 16	14.98

News Page 1 of 1

Nothing yet